Causes and prognostic factors for early death in patients with acute promyelocytic leukemia treated with single-agent arsenic trioxide-Reference-Cited by-同舟云学术

Causes and prognostic factors for early death in patients with acute promyelocytic leukemia treated with single-agent arsenic trioxide

Published:2017-09-22 Issue:12 Volume:96 Page:2005-2013
ISSN:0939-5555
Container-title:Annals of Hematology
language:en
Short-container-title:Ann Hematol

Author:

Hou Jinxiao,Wang Shuye,Zhang Yingmei,Fan Dachuan,Li Haitao,Yang Yiju,Ge Fei,Hou Wenyi,Fu Jinyue,Wang Ping,Zhao Hongli,Sun Jiayue,Yang Kunpeng,Zhou Jin,Li Xiaoxia^ORCID

Funder

Natural Science Foundation of Heilongjiang Province of China

the National Natural Science Foundation of China

Medical Scientific Research Items (MSRI) in Hainan Province

the Fund for Doctors of the First Affiliated Hospital, Harbin Medical University

China Postdoctoral Science Foundation (CN)

Foundation of Heilongjiang Educational Committee

the Major State Basic Research Development Program of China

Natural Science Foundation of Heilongjiang Province of China

the Health Department Foundation of Heilongjiang Province

Publisher

Springer Science and Business Media LLC

Subject

Hematology,General Medicine

Link

http://link.springer.com/article/10.1007/s00277-017-3130-7/fulltext.html

Reference23 articles.

1. Tallman MS, Andersen JW, Schiffer CA et al (1997) All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med 337:1021–1028. https://doi.org/10.1056/NEJM199710093371501

2. Wang ZY, Chen Z et al (2008) Acute promyelocytic leukemia: from highly fatal to highly curable. Blood 111:2505–2515. https://doi.org/10.1182/blood-2007-07-102798

3. Chen SJ, Zhou GB, Zhang XW, Mao JH, de Thé H, Chen Z (2011) From an old remedy to a magic bullet: molecular mechanisms underlying the therapeutic effects of arsenic in fighting leukemia. Blood 117:6425–6437. https://doi.org/10.1182/blood-2010-11-283598

4. Mathews V, George B, Lakshmi KM et al (2006) Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. Blood 107:2627–2632. https://doi.org/10.1182/blood-2005-08-3532

5. McClellan JS, Kohrt HE, Coutre S et al (2012) Treatment advances have not improved the early death rate in acute promyelocytic leukemia. Haematologica 97:133–136. https://doi.org/10.3324/haematol.2011.046490

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Diagnosis and management of acute promyelocytic leukemia: Brazilian consensus guidelines 2024 on behalf of the Brazilian Association of Hematology, Hemotherapy and Cellular Therapy;Hematology, Transfusion and Cell Therapy;2024-05

2. Սուր պրոմիելոցիտային լեյկեմիայի ընդհանուր բնութագիրը, կլինիկական պատկերը և բուժման մոտեցումները;Medical Science of Armenia;2024-03-19

3. Causes and risk factors for early death in adult patients with acute promyelocytic leukemia: a real-life experience;Hematology, Transfusion and Cell Therapy;2024-03

4. Improvement of Early Death in Acute Promyelocytic Leukemia: A Population-Based Analysis;Clinical Lymphoma Myeloma and Leukemia;2023-02

5. Early mortality continues to be a barrier to excellent survival in childhood acute promyelocytic leukemia: a retrospective study of 62 patients spanning 17 years;Pediatric Hematology and Oncology;2022-07-18